- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Interventions
- 18F-PF974, 18F-florbetaben
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Mild Cognitive Impairment clinical trials
Directory of U.S. ClinicalTrials.gov public records for Mild Cognitive Impairment. Browse Mild Cognitive Impairment recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 13, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
How Mild Cognitive Impairment studies are organized in the registry
MCI is the registry’s main gateway term for early-stage memory and Alzheimer’s-prevention research; “amnestic MCI” labels the memory-specific subset. The portfolio includes a high share of observational cohort studies from memory clinics, so the study-type filter cleanly separates those from interventional trials.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Alzheimer Disease
- Interventions
- Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
- Conditions
- Mild Cognitive Impairment, Chronic Kidney Diseases
- Interventions
- Home-based walking exercise, Attention control
- Behavioral · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • New York, New York
- Conditions
- Cognitive Assessment, Psychological Function, GI Health
- Interventions
- Pecan snack, Pretzel snack
- Biological
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Mild Cognitive Impairment
- Interventions
- Olfactory Memory Training, Visual Memory Training
- Behavioral
- Lead sponsor
- Jeffrey Motter
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild Cognitive Impairment
- Interventions
- Glycine, N-acetylcysteine (NAC), Alanine
- Dietary Supplement
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- MCI
- Interventions
- Active tES, Cognitive Interventions
- Device · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mild Cognitive Impairment, Alzheimer Dementia (AD)
- Interventions
- Closed-loop TBS, Open-loop TBS
- Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
About this Mild Cognitive Impairment clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Mild Cognitive Impairment as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Mild Cognitive Impairment.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Mild Cognitive Impairment.